Document:

Exhibit 4.6

 

Form of Note

 

THIS NOTE HAS NOT BEEN REGISTERED
WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY
NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS.

 

CADRENAL THERAPEUTICS, INC.

 

10% PROMISORRY NOTE

 

	Issuance Date:_______________, 2022	 	Original Principal Amount: $ ________________
	 	 	 
	Note No. _____	 	 

 

FOR VALUE
RECEIVED, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company” or the “Maker”),
hereby promises to pay to the order of ______________________ (the “Subscriber”), or its registered assigns (together with the
Subscriber, the “Holder”), the amount set out above as the Original Principal Amount, as reduced pursuant to the terms
hereof (the “Principal”), when due, whether upon the Maturity Date (as defined below), acceleration, redemption or
otherwise (in each case in accordance with the terms hereof) and to pay interest (“Interest”) on any outstanding Principal
at the applicable Interest Rate from the date set out above as the Issuance Date (the “Issuance Date”) until the same
becomes due and payable, upon the Maturity Date or acceleration or otherwise (in each case in accordance with the terms hereof).

 

The Original
Principal Amount is____________________Dollars ($_________). For purposes hereof, the term “Outstanding Balance” means the
Original Principal Amount, as reduced or increased, as the case may be, pursuant to breach or otherwise, plus any accrued but unpaid interest,
collection and enforcements costs, and any other fees or charges incurred under this Note.

 

This Note
is being issued pursuant to the terms of a subscription agreement dated as of_____ ___, 2022 between the Maker and the Subscriber and exhibits
thereto (collectively, the “Transaction Documents”). Unless otherwise defined herein, all capitalized terms, when used
in this Note, shall have the same meaning as they are defined in the Transaction Documents.

 

		1.	GENERAL TERMS

 

(a)
Payment of Principal. The Company or the common stock of any successor in interest to the Maker (each the “Common
Stock”) as contemplated hereby, this Note, together with all accrued interest hereon at the Interest Rate, shall be due and
payable on the earlier of the Company’s completion of its IPO (as defined below) or November 30, 2023 (the “Maturity Date”)
in the event that within 12 months of the Issuance Date, the Maker shall not have consummated an initial public offering of its Common
Stock and the listing or trading of its Common Stock on a “Qualified Securities Market”, as defined below (the “IPO”).

 

     

     

    

 

(b)
Interest. Interest shall accrue from the Issuance Date on the Original Principal Amount or other outstanding Principal at
an annual rate of ten percent (10%) (the “Interest Rate”) and all accrued interest shall be fully paid on the Maturity
Date (or sooner as provided herein) to the Holder or its assignee in whose name this Note is registered on the records of the Maker in
cash.

 

		2.	EVENTS OF DEFAULT.

 

Whenever used herein,
an “Event of Default” means the occurrence and continuation of any one of the following events, whatever the reason,
and whether it shall be voluntary or involuntary, or effected by operation of law or pursuant to any judgment, decree or order of any
court, or any order, rule or regulation of any administrative or governmental body:

 

(a)
The Maker’s failure to pay to the Holder any amount of Principal, Interest, or other amounts when and as due under this Note;
or

 

(b)
A material breach by the Company of any material representation, warranty or covenant contained in the Transaction Documents or
a material breach by the Company of any material representation, warranty or covenant contained in the Subscription Agreement, that, if
capable of cure, is not cured within 30 days from the date such breach has occurred; or

 

(c)
The Maker or any subsidiary of the Maker shall commence, or there shall be commenced against the Maker or any subsidiary of the
Maker under any applicable bankruptcy or insolvency laws as now or hereafter in effect or any successor thereto, or the Maker or any subsidiary
of the Maker commences any other proceeding under any reorganization, arrangement, adjustment of debt, relief of debtors, dissolution,
insolvency or liquidation or similar law of any jurisdiction whether now or hereafter in effect relating to the Maker or any subsidiary
of the Maker or there is commenced against the Maker or any subsidiary of the Maker any such bankruptcy, insolvency or other proceeding
which remains undismissed for a period of ninety-one (91) days; or the Maker or any subsidiary of the Maker is adjudicated insolvent or
bankrupt; or any order of relief or other order approving any such case or proceeding is entered; or the Maker or any subsidiary of the
Maker suffers any appointment of any custodian, private or court appointed receiver or the like for it or any substantial part of its
property which continues undischarged or unstayed for a period of ninety-one (91) days; or the Maker or any subsidiary of the Maker makes
a general assignment for the benefit of creditors; or the Maker or any subsidiary of the Maker shall fail to pay, or shall state that
it is unable to pay, or shall be unable to pay, its debts generally as they become due; or the Maker or any subsidiary of the Maker shall
call a meeting of its creditors with a view to arranging a composition, adjustment or restructuring of its debts; or the Maker or any
subsidiary of the Maker shall by any act or failure to act expressly indicate its consent to, approval of or acquiescence in any of the
foregoing; or any corporate or other action is taken by the Maker or any subsidiary of the Maker for the purpose of effecting any of the
foregoing.

 

		3.	PREPAYMENT. This Note may be prepaid by the Company.

 

		4.	REISSUANCE OF THIS NOTE.

 

Upon receipt
by the Maker of evidence reasonably satisfactory to the Maker of the loss, theft, destruction or mutilation of this Note, and, in the
case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Maker in customary form and, in the case of
mutilation, upon surrender and cancellation of this Note, the Maker shall execute and deliver to the Holder a new Note representing the
outstanding Principal.

 

    2

     

    

 

5. NOTICES. Any notices, consents, waivers
or other communications required or permitted to be given under the terms shall be handled according to the Notice clause in the
Subscription Agreement. The addresses for such communications shall be:

 

If to the Maker:

 

Quang Pham, CEO

Cadrenal Therapeutics, Inc.

822 A1A North, Suite 320

Ponte Vedra, Florida 32082

Email:quang.pham@cadrenal.com

 

If to the Holder:

 

 

6.
APPLICABLE LAW AND VENUE. This Note shall be governed by and construed in accordance with the laws of the State of New York, without
giving effect to conflicts of laws thereof. Any action brought by either party against the other concerning the transactions contemplated
by this Agreement shall be brought only in the state courts of New York or in the federal courts located in New York County, in the State
of New York. Both parties and the individuals signing this Agreement agree to submit to the jurisdiction of such courts.

 

7.
WAIVER. Any waiver by the Holder of a breach of any provision of this Note shall not operate as or be construed to be a waiver
of any other breach of such provision or of any breach of any other provision of this Note. The failure of the Holder to insist upon strict
adherence to any term of this Note on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter
to insist upon strict adherence to that term or any other term of this Note. Any waiver must be in writing.

 

		8.	MISCELLANEOUS

 

(a)
Lawful Money; Costs of Collection. All amounts payable hereunder are payable in lawful money of the United States. The Company
agrees to pay all costs of collection when incurred, including reasonable attorneys’ fees and costs, whether or not a suit or action
is instituted to enforce this Note, including but not limited to court costs, appraisal fees, the cost of searching records, obtaining
title reports and title insurance and trustee’s fees, to the extent permitted by applicable law.

 

(b)
No Offset; Holder in Due Course. All payments under this Note made by or on behalf of the Company shall be made without
setoff or counterclaim and free and clear of, and without deduction or withholding for or on account of, any federal, state, or local
taxes. The Company waives any right of offset it now has or may hereafter have against Holder and its successors and assigns as to this
Note (but retains any such rights as to any other prior or future transaction between these parties), and agrees to make the payments
called for hereunder in accordance with the terms hereof. The holder hereof and all successors thereof shall have all the rights of a
holder in due course as provided in the Delaware Uniform Commercial Code and other laws of the State of Delaware.

 

(c)
Waivers. The Company and any endorsers, guarantors or sureties hereof severally waive presentment and demand for payment,
notice of intent to accelerate maturity, protest or notice of protest or nonpayment, bringing of suit and diligence in taking any action
to collect any sums owing hereunder or in proceeding against any of the rights and properties securing payment hereunder; expressly agree
that this Note, or any payment hereunder, may be extended from time to time; and consent to the acceptance of further security or the
release of any security for this Note, all without in any way affecting the liability of the Company and any endorsers or guarantors hereof.
No extension of time for the payment of this Note, or any installment hereof, made by agreement by the holder hereof with any person now
or hereafter liable for the payment of this Note, shall affect the original liability under this Note of the Company, even if the Company
(or any entity comprising the Company) is not a party to such agreement.

 

    3

     

    

 

(d)
Usury Protection. The parties hereto intend to conform strictly to the applicable usury laws. In no event, regardless of
any provisions contained therein or in any other document executed or delivered in connection herewith, shall the holder hereof ever be
deemed to have contracted for or be entitled to receive, collect or apply as interest on this Note, any amount in excess of the maximum
amount permitted by applicable law (the “Maximum Rate”). In no event, whether by reason of demand for payment, prepayment,
acceleration of the maturity hereof or otherwise, shall the interest contracted for, charged or received by the holder hereunder or otherwise
exceed the Maximum Rate. If for any circumstance whatsoever interest would otherwise be payable to the holder in excess of the maximum
lawful amount, the interest payable to the holder shall be reduced automatically to the Maximum Rate and any payment received in excess
of such amount shall be applied to the outstanding principal balance of the Note.

 

(e)
Entire Agreement. This Note, the other Transaction Documents, and all other documents and instruments contemplated hereby
and thereby together constitute the entire agreement between and among the parties pertaining to the subject matter hereof. No supplement,
modification or amendment of this Note shall be binding unless executed in writing by the parties. No waiver shall be binding unless executed
in writing by the party making the waiver. No provision of this Note shall be interpreted for or against the drafting party.

 

(f)
Commercial Purpose. The Company agrees that no funds advanced under this Note shall be used for personal, family or household
purposes, and that all funds advanced hereunder shall be used solely for business, commercial, investment or other similar purposes.

 

(g)
Successors and Assigns. All the terms and provisions of this Note shall be binding upon and inure to the benefit of the
parties to this Note and their respective successors and assigns.

 

(h)
Assignment. The Company may not, voluntarily or involuntarily, directly or indirectly, by operation of law or otherwise,
sell, transfer, assign, hypothecate, pledge or in any way alienate this Note or any right or interest in this Note (each a “Transfer”)
without Holder’s prior written consent, which Holder may withhold in its sole and absolute discretion. Any consent by Holder to
any Transfer shall not constitute consent to any other Transfer. Holder may freely Transfer its interest, rights, or title in or to this
Note or the other Transaction Documents in Holder’s sole and absolute discretion.

 

(i)
Construction. Whenever used in this Note, the terms “including,” “include,” “includes”
and the like are not intended as terms of limitation, and, hence, shall be deemed to be followed by “without limitation.”

 

(j)
Severability. If any provision of this Note, as applied to any party or to any circumstance, shall be found by a court of
competent jurisdiction to be void, invalid or unenforceable, the same shall in no way affect any other provision of this Note, the application
of any such provision in any other circumstance, or the validity or enforceability of this Note, and any provision which is found to be
void, invalid or unenforceable shall be curtailed and limited only to the extent necessary to bring such provision within the requirements
of the law.

 

(k)
Survival of Terms. The terms and provisions of this Note shall survive the Maturity Date until full payment of all amounts
due hereunder.

 

(l)
Preferential Payment. If at any time any payment made pursuant to this Note is deemed to have been a voidable preference,
fraudulent conveyance or other similar conveyance or preferential payment under any bankruptcy, insolvency or other debtor relief or similar
law, then the obligation to make such payment shall survive any cancellation or satisfaction of this Note or return of this Note to the
Company and shall not be discharged or satisfied with any such payment or cancellation. Such payment shall instead remain a valid and
binding obligation enforceable in accordance with the terms of this Note and shall be immediately due and payable.

 

    4

     

    

 

(m) Relief
From Stay. As an additional inducement to and material consideration for Holder agreeing to execute this this Note and the other
Transaction Documents, the Company agrees that in the event a Bankruptcy or Judicial Action (as hereinafter defined in this Section
8(n)) is commenced which subjects Holder to any stay in the exercise of Holder’s rights and remedies under this Note or the
other Transaction Documents, including, but not limited to, the automatic stay imposed by Section 362 of the United States Bankruptcy
Code (individually and collectively, “Stay”), then the Company irrevocably consents and agrees that such Stay shall
automatically be lifted and released against Holder, and Holder shall thereafter be entitled to exercise all of its rights and remedies
against the Company that is or could be subject any Stay under this Note or the other Transaction Documents. Nothing contained herein
shall limit or prevent Holder from exercising all of its rights and remedies against the Company that is not the subject any Stay under
this Note or the other Transaction Documents. The Company acknowledges that it is knowingly, voluntarily, and intentionally waiving its
rights to any Stay and agrees that the benefits provided to the Company under the terms of this Note are valuable consideration for such
waiver. As used in this Section 8(n), the term “Bankruptcy or Judicial Action” shall mean any voluntary or
involuntary case filed by or against the Company under the United States Bankruptcy Code, or any voluntary or involuntary petition in
composition, readjustment, liquidation, or dissolution, or any state and federal bankruptcy law action filed by or against the Company,
any action where a the Company is adjudicated as bankrupt or insolvent, any action for dissolution of the Company, or any action in furtherance
of any of the foregoing, or any other action, case, or proceeding that has the effect of staying (or in which a stay is being obtained
against) the enforcement by Holder of its rights and remedies under the this Note or the other Transaction Documents.

 

Except to enforce the terms of the
Transaction Documents, the Company shall not take any action and shall not fail to take any action which such action or omission will
or might tend to interfere with, delay, enjoin or otherwise prohibit the commencement, continuation or completion of efforts by Holder
to enforce its remedies under this Note or the other Transaction Documents, or applicable law. Without limiting the generality of the
foregoing and except to enforce the terms of the Transaction Documents, the Company waives its right, if any, to seek or obtain a stay,
injunction or other form of order prohibiting in any way any act necessary or appropriate for the commencement or completion of Holder’s
enforcement of its remedies under the this Note or the other Transaction Documents, or applicable law (without limiting the generality
of the foregoing, such waiver extends to such rights which may exist under any statute or rule relating to bankruptcy cases, including,
without limitation, 11 U.S.C. § 105, 11 U.S.C. § 301, 11 U.S.C. § 302, 11 U.S.C. § 303, 11 U.S.C. § 304, 11 U.S.C.
§ 362, 11 U.S.C. § 348, 11 U.S.C. § 706, 28 U.S.C. § 157, 28 U.S.C. § 158, Federal Rule of bankruptcy Procedure
(“FRBP”) 3007, FRBP 3008, FRBP 3012, FRBP 8005, FRBP 9023, FRBP 9024, or FRBP 9029).

 

9.
AMENDMENT AND WAIVER OF RIGHTS. This Note may be amended and the observance of any term hereof may be waived (either generally
or in a particular instance either retroactively or prospectively) only by a written instrument executed by the Maker and the Holder.

 

		10.	WAIVER OF RIGHT TO TRIAL BY JURY.

 

EACH PARTY TO THIS NOTE HEREBY
EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (1) ARISING UNDER THIS NOTE, THE OTHER TRANSACTION
DOCUMENTS, OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION THEREWITH, OR (2) IN ANY WAY CONNECTED
WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS NOTE OR ANY OTHER INSTRUMENT,
DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH, OR THE TRANSACTIONS RELATED HERETO OR THERETO, IN EACH CASE WHETHER
NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT
ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY. THE PARTIES HERETO HEREBY AGREE THAT
THE PROVISIONS CONTAINED HEREIN HAVE BEEN FAIRLY NEGOTIATED ON AN ARM’S-LENGTH BASIS, WITH BOTH SIDES AGREEING TO THE SAME KNOWINGLY
AND BEING AFFORDED THE OPPORTUNITY TO HAVE THEIR RESPECTIVE LEGAL COUNSEL CONSENT TO THE MATTERS CONTAINED HEREIN. ANY PARTY TO THIS NOTE
MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO
THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY AND THE AGREEMENTS CONTAINED HEREIN REGARDING THE APPLICATION OF JUDICIAL REFERENCE IN THE
EVENT OF THE INVALIDITY OF SUCH JURY TRIAL WAIVER.

 

    5

     

    

 

IN WITNESS WHEREOF, each of the Maker
has caused this Note to be duly executed by a duly authorized officer as of the date set forth above.

 

	 	Cadrenal Therapeutics, Inc.
	 	 
	 	By:	 
	 	Name: 	 Quang Pham
	 	Title:	 Chief Executive Officer

 

Note No. [   ]

 

 

6Exhibit 4.7

 

NEITHER THIS SECURITY NOR THE SECURITIES
FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

FORM OF AMENDED AND RESTATED
COMMON STOCK PURCHASE WARRANT

CADRENAL THERAPEUTICS, INC.

 

	Warrant No. _______
  	Issue Date:  __________2022

 

This Warrant Replaces Warrant No. _______ in its entirety

Original Warrant No.: _________ (cancelled and replaced by
this Warrant No. ______)

 

THIS AMENDED AND RESTSATED COMMON STOCK
PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [    ] or
any registered assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on
exercise and the conditions hereinafter set forth, at any time following the Issue Date (the “Initial Exercise
Date”) and on or prior to the close of business on _________________________ , 2027,1 subject
to the provisions of Section 2 below (the “Termination Date”) but not thereafter, to subscribe for and
purchase from Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), up to [     ]
shares of Common Stock (the “Warrant Shares”). The purchase price of one share of Common Stock under this
Warrant shall be $1.00.

 

Section 1. Definitions.
For the purposes hereof, in addition to the terms defined elsewhere in this Warrant, (a) capitalized terms not otherwise defined herein
shall have the meanings set forth in the Subscription Agreement entered into by the Company and the Holder of even day herewith and (b)
the following terms shall have the following meanings:

 

“Business
Day” means any day except any Saturday, any Sunday, any day which shall be a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Common
Stock” means the shares of common stock, $0.001 par value per share, of the Company.

 

“Common
Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common
Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive Common Stock.

 

 

1 Five years from the Issue Date

 

     

     

    

 

“Exercise Period”
shall have the meaning as that term is defined in Section 2(a) below.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the New York Stock Exchange is open for business.

 

“Trading
Market” means the following markets or exchanges on which the Common Stock may be listed or quoted for trading on the date
in question: the NYSE MKT, LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange.

 

“Transfer Agent” means Transfer
Online, Inc.

 

Section 2. Exercise.

 

a) Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date (the “Exercise Period”) by
delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered
Holder at the address of the Holder appearing on the books of the Company) of a duly executed notice of exercise
(“Notice of Exercise”) form attached hereto as Exhibit A; and, within three (3) Trading Days of the
date said Notice of Exercise is delivered to the Company, the Company shall have received payment of the aggregate Exercise Price of
the shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank, provided however, that if the
Holder of this Warrant has not elected to exercise this Warrant prior to the earlier of the consummation of the Company’s
initial public offering or the due date of the promissory note issued to the Holder by the Company in the principal amount of
$125,000, dated November 30, 2022 (the “Note”) then this Warrant shall automatically be exercised upon the consummation
of the Company’s initial public offering. At such time, in place of payment of the aggregate Exercise Price in cash, the
principal amount of the Note, will be deemed repaid in full, and such deemed repayment will be considered payment in full of the aggregate Exercise Price of
this Warrant. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in
full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the
earlier of the date the final Notice of Exercise is delivered to the Company or consummation of the Company’s initial public
offering. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the
applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. In the event of any dispute or discrepancy, the records of the Company shall be
controlling and determinative in the absence of manifest error.

 

b) Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $1.00.

 

    2

     

    

 

 c) Mechanics of Exercise.

 

i. Delivery
of Warrant Shares Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the Company’s transfer
agent (the “Transfer Agent”) to the Holder by crediting the account of the Holder’s prime broker with
the Depository Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”) system if the Company
is then a participant in such system and either (A) there is an effective registration statement for its initial public offering registering
the Warrants Shares, in which case the Holder will simultaneously exercise this Warrant upon the effectiveness of such registration statement,
(B) there is a registration statement permitting the resale of the Warrant Shares by the Holder or (C) the shares are eligible for resale
without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of certificates to the address specified
by the Holder in the Notice of Exercise within four (4) Trading Days from the delivery to the Company of the Notice of Exercise Form,
surrender of this Warrant (if required) and payment of the aggregate Exercise Price as set forth above (the “Warrant Share
Delivery Date”). This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company.
The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed
to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company
of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section 2(c)(v) prior to the issuance of such
shares, have been paid.

 

ii. Delivery
of Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon
surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver
to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new
Warrant shall in all other respects be identical with this Warrant.

 

iii. Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates representing
the Warrant Shares pursuant to Section 2(c)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such
exercise.

 

iv. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at
its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise
Price or round up to the next whole share.

 

v. Charges,
Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company,
and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the assignment form (“Assignment Form”) attached hereto
as Exhibit B duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to
reimburse it for any transfer tax incidental thereto.

 

vi. Closing
of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.

 

    3

     

    

 

Section 3. Certain Adjustments.

 

a) Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise make a
distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common
Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii)
subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split)
outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any
shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which
the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of shares issuable
upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged.
Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders
entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.

 

b) Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

 c) Notice to Holder.

 

i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring
such adjustment; provided, however, that the Company may satisfy the notice requirement in this Section 3(c) by filing such information
with the Commission on its EDGAR system pursuant to a Current Report on Form 8-K or Quarterly Report on Form 10-Q or Annual Report on
Form 10-K.

 

ii. Notice to Allow
Exercise by Holder. If (A) the Company shall declare a dividend or any other distribution in whatever form (other than a stock
split) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock (excluding any granting or issuance of rights to all of the Company’s stockholders pursuant to a stockholder rights
plan), (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be
required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party,
any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common
Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to
the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the
applicable record or effective date hereinafter specified (unless such information is filed with the Commission on its EDGAR system
in which case a notice shall not be required), a notice stating (x) the date on which a record is to be taken for the purpose of
such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or
(y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their
shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger,
sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof
shall not affect the validity of the corporate action required to be specified in such notice. The Holder is entitled to exercise
this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice.

 

    4

     

    

 

Section 4. Transfer of Warrant.

 

a) Transferability.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned, may be exercised by a new holder for the purchase
of Warrant Shares without having a new Warrant issued.

 

b) Warrants.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this Warrant
except as to the number of Warrant Shares issuable pursuant thereto.

 

c) Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.

 

Section 5. Miscellaneous.

 

a) No
Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights as a shareholder
of the Company prior to the exercise hereof.

 

b) Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

 

    5

     

    

 

d) Authorized Shares.

 

The Company covenants
that, upon effectiveness of the Company’s initial public offering, it will reserve from its authorized and unissued Common Stock
one hundred (100%) of the number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. In case such amount of Common Stock is insufficient at any time, the Company shall call and hold a special meeting
to increase the number of authorized shares of common stock. Management of the Company shall recommend to shareholders to vote in favor
of increasing the number of authorized shares of common stock.

 

The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing
stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under
this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as
provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid
and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes
in respect of any transfer occurring contemporaneously with such issue).

 

Except and to
the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its amended
and restated certificate of incorporation, as amended, or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of
this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as
may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the
generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon
such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use
commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof.

 

e) Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the laws of the State of Delaware.

 

f) Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions
upon resale imposed by state and federal securities laws.

 

g) Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all rights hereunder
terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

    6

     

    

 

h) Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the addresses provided by the Holder of this Warrant.

 

i) Limitation
of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price
of any Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

 

j) Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.

 

k) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions of this
Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable by the Holder or
holder of Warrant Shares.

 

l) Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holders of a majority
of the Warrant Shares underlying the Warrants of the Company issued on the Closing Date that are outstanding as of such date.

 

m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

n) Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

[Signature Page Follows.]

 

    7

     

    

 

IN WITNESS WHEREOF, the Company has caused this Warrant to
be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	CADRENAL THERAPEUTICS, INC.	 
	 	 
	By:	 	 
	Name:	Quang Pham	 
	Title:	Chief Executive Officer	 

 

Agreed and acknowledged on this _____ day of ____________,
2022

 

INVESTOR:

 

	By:	 	 
	Name:	 	 
	Title:	 	 

 

    8

     

    

 

EXHIBIT A

 

NOTICE OF EXERCISE

 

TO:

 

(1) The undersigned hereby
elects to
purchase                      Warrant
Shares of the Company pursuant to the terms of the attached Warrant and tenders herewith payment of the exercise price in full,
together with all applicable transfer taxes, if any.

 

(2) Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified
below:

 

____________________________

 

The Warrant Shares shall be delivered to the following DWAC
Account Number or by physical delivery of a certificate to:

 

____________________________

 

____________________________

 

____________________________

 

(3) Accredited
Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act
of 1933, as amended.

 

[SIGNATURE OF HOLDER]

 

Name of Investing Entity:

 

________________________________________________________________

 

Signature
of Authorized Signatory of Investing Entity:

 

________________________________________________________________

 

Name of Authorized Signatory:

________________________________________________________________

 

Title of Authorized Signatory:

 

________________________________________________________________

 

Date:

 

________________________________________________________________

 

     

     

    

 

EXHIBIT B

 

ASSIGNMENT FORM

 

(To assign the foregoing
warrant, execute

 this form and supply required information. Do

 not use this form to exercise the warrant.)

 

FOR VALUE RECEIVED, [            ] all of
or [            ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

_____________________________________whose address is

 

______________________________________________________________.

 

______________________________________________________________

 

Dated:                   ,           

  

Holder’s Signature:                                

 

Holder’s Address:                                

 

Signature Guaranteed:                                                                    

 

NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed
by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]